Bausch + Lomb Discontinues BL1107 Eye Drops for Glaucoma After Phase 2 Miss
The company will discontinue the topical program but continue advancing a sustained-release implant for geographic atrophy.
/ 3 items
#BLCO↓
Morgan Stanley Issues Key Rating Changes Across MedTech and Healthcare Stocks
Morgan Stanley updates ratings for Inspire Medical, DexCom, and Bausch + Lomb, highlighting slowing growth, improving operations, and strong long-term pipelines.
Jana Partners Pushes Cooper Cos. Toward Deal with Bausch + Lomb
Activist investor Jana Partners targets Cooper Cos., advocating for a contact lens merger with Bausch + Lomb and strategic changes to boost shareholder value amid declining performance.